News from Atom Bioscience

Atom Bioscience Marks Gout Awareness Day by Urging Increased Patient Education on Debilitating Effects of the Chronic Disease
PRESS RELEASE Atom Bioscience Marks Gout Awareness Day by Urging Increased Patient Education on Debilitating...
Atom Bioscience Names UC San Diego Professor Robert Terkeltaub, M.D., to its Scientific Advisory Board
PRESS RELEASE Atom Bioscience Names UC San Diego Professor Robert Terkeltaub, M.D., to its Scientific...
Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1 Inhibitor for Chronic Gout
PRESS RELEASE Atom Bioscience Announces Positive Results of Phase 2a China Clinical Trial of Its URAT1...
Atom Bioscience to Present at BIO CEO & Investor Conference on February 6, 2023, at the Marriott Marquis, New York City
PRESS RELEASE Atom Bioscience to Present at BIO CEO & Investor Conference on February 6, 2023, at...
Atom Bioscience Names Stanford University Professor Vibeke Strand, M.D., to its Scientific Advisory Board
PRESS RELEASE Atom Bioscience Names Stanford University Professor Vibeke Strand, M.D., to its Scientific...
Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic Gout at American College of Rheumatology Annual Meeting, Nov. 10 – 14, in Philadelphia, PA
PRESS RELEASE Atom Bioscience to Present Final Data from its Positive Phase 2a Clinical Trial in Chronic...
Atom Bioscience Announces Abstract for Its Phase 2a Gout Study Accepted for American College of Rheumatology Annual Meeting, Nov. 10 – 14, in Philadelphia
PRESS RELEASE Atom Bioscience Announces Abstract for Its Phase 2a Gout Study Accepted for American College...
Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International Convention, June 13 – 16, 2022, San Diego, CA
PRESS RELEASE Atom Bioscience to Update Clinical Development of New Drug to Treat Gout at BIO International...
On Gout Awareness Day, Let’s Put the Myths to Rest
PRESS RELEASE On Gout Awareness Day, Let’s Put the Myths to Rest Genetic abnormalities are the real...
Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout
PRESS RELEASE Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat...

Industry News

Clinical Trials Arena: Atom Bioscience reports positive Phase IIa chronic gout therapy trial data
Kidney Disease Among Top Contributors to Excess Death Risk in Veterans With Gout
Arthritis & Rheumatology: Study Compares Gout Treatments with Different Mechanisms of Action - URAT1 Inhibitor vs Xanthine Oxidase Inhibitor
Arthritis & Rheumatology: Study Compares Gout Treatments with Different Mechanisms of Action –...
Healthline: How Gout Flare-ups May Increase the Risk of Heart Attack, Stroke
Physicians Weekly: Urate-Lowering Treatments Compared for Gout
ATOM_LinkedInBioworldstory
BioWorld: Atom Bioscience Planning Phase III Gout Trial After Encouraging Mid-Stage Readout
BioSpace: Atom Bioscience Announces Positive Phase 2a Results For Investigational New Drug to Treat Chronic Gout
Healio.com: 'Horribly mismanaged': Debate over gout treatment rages as cases surge
Gout and Heart Disease: Why You're at Increased Risk
Physicians Weekly: Analyzing the Genetics of Hyperuricemia & Gout in Post-Partum Racial/Ethnic Groups